What is Exogenesis?
Headquartered in Billerica, Massachusetts, Exogenesis is at the forefront of surface science, developing a unique platform technology named NanoAccel. This platform leverages Accelerated Neutral Atom Beam (ANAB) and Gas Cluster Ion Beam (GCIB) technologies to precisely modify and control material surfaces at the nanoscale without applying coatings or causing sub-surface damage. Exogenesis's innovative approach targets a diverse array of applications across the biomedical, optical, and semiconductor industries, positioning it as a key player in advanced materials innovation.
How much funding has Exogenesis raised?
Exogenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Exogenesis?
As a company operating within a large-scale, late-stage funding environment, Exogenesis is poised for significant growth and commercialization. The recent strategic investment signals strong confidence from its backers in the company's technology and market potential. Future developments are likely to focus on scaling production, expanding market reach into its target sectors, and potentially exploring new applications for its versatile surface modification capabilities. This capital will be instrumental in solidifying Exogenesis's position as a leader in nanoscale surface engineering.
See full Exogenesis company page
